East China Medicine Big Break Attack Over $6 Billion Star Drug.

QX001S is the world's first usinu monobio-like drug developed in accordance with guidelines for NMPA, FDA, and EMA biosysor drugs.
Usnu monoantigen is the world's first all-human source "double-targeted" IL-12 and IL-23 recombinant all-humanized monoclonal antibody injections developed by Johnson and Johnson, and the current approved adaptations include moderate to severe plaque psoriasis, moderate to severe Crohn's disease (CD), active psoriasis arthritis, moderate to severe active ulcer colitis (UC) and so on.
Figure 1: Johnson and Johnson's global sales of Usnou mono-injection fluids (in millions of dollars) Source: Intranet multinational listed companies sales database Usnu mono-injections for Johnson and Johnson's home products, in recent years, global sales continued to grow rapidly, in 2019 sales revenue of $6.361 billion, the first half of 2020 under the impact of the epidemic is still against the trend of growth of 18.7 percent, sales revenue reached $3.516 billion.
At present, there is no Usnu monobio-similar drugs approved worldwide, but also only the domestic letter biological (QX001S injection), BAIOtai (BAT2206 injection) two companies have been approved clinical products.
Figure 2: Registration of domestic clinical trials of QX001S injections Source: China Drug Clinical Trials Public Library QX001S Injections obtained clinical approval in 2018 and completed the first clinical trial of Phase I drug administration , the progress of research and development in the world in a leading position, Espresso Bio plans to start QX001S in early 2021 to treat adults with severe plaque psoriasis Phase III research, East China Medicine is expected to harvest a heavy monoantigenic biological similar drugs in the future.
With the profound changes in the domestic pharmaceutical market environment, East China Pharmaceuticals under the "transformation and innovation" strategy will be "endocrine, autoimmune diseases, tumors" three major disease areas as the core direction of innovative product layout, and strive to start in 2022, to maintain the annual listing of innovative products a benign pace of development, to achieve the 2025 innovation business sector accounted for 30% of the overall industrial revenue phase goal. Table
: East China Medicine in the study of a class of 1 new drugs Source: Minet China Drug Clinical Trials Public Library Minet data show that there are currently 4 types of 1 new drugs in East China Medicine in research, all belong to chemical drugs, of which Mehuatine tablets progress the fastest, treatment of local late stage Phase III clinical trials of metastatic non-scaly non-small cell lung cancer have been initiated, and the product is a second-generation EGFR-TKI targeted drug, and the company is seeking to report directly the results of Phase II one-arm clinical trials with mevartini for first- /second-line rare gene mutations.
TTP273 tablets for East China Medicine introduced oral GLP-1 innovative drugs, type 2 diabetes adaptability has been carried out phase I clinical; HD118 tablets for the company's technology transfer of DPP-4 inhibitors, improve blood glucose control and adaptation in adult patients with type 2 diabetes has completed Phase I clinical;
source: In-net database, listed companies announcement Note: data statistics as of August 19, if there are omissions, welcome to point the right!